The study included 11 subjects, 3 of whom received an additional pre-treatment of low dose parental cG50 antibody with a strategy to block CAIX CAR recognition of cognate antigen on normal liver tissue while still leaving accessible CAIX at RCC tumor sites. Here, CA9 is linked to neoplasm.